Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
583
resultados
Última actualización
22/10/2025 [06:50:00]
Resultados 175 a 200 de 583
Resumen de: CN120559248A
The invention discloses an exosome detection method for Alzheimer's disease, and relates to exosome separation and extraction. The method comprises the following steps: modifying the surface of a biological sensing chip, and forming an S-Au bond by utilizing MUA and a gold film to construct a self-assembled monomolecular layer rich in carboxyl; activating carboxyl by using an EDC-NHS solution, anchoring an antibody capable of recognizing exosome membrane protein secreted by brain-derived neuronal cells, and closing non-specific sites by using bovine serum albumin; a serum sample and a chip are incubated, exosomes are separated through a glycine buffer solution with the pH value being 2.0, the pH value is adjusted to be neutral, and a lysis solution containing 1% of Triton X-100 is added for lysis; and finally, mounting an integrated optical fiber probe to measure a reflection spectrum and monitor resonance wavelength, and realizing quantitative detection by combining multi-marker conjoint analysis. The exosome can be enriched and purified with high purity and high specificity, the process is simple, the detection sensitivity is high, and the AD detection accuracy is remarkably improved. The process is simple, complex operations such as ultracentrifugation are avoided, and the detection time is shortened.
Resumen de: CN120554274A
The invention belongs to the field of biological medicine and discloses preparation and application of an indolium multifunctional photosensitizer QA-26 with A beta protein specific response, the structural formula of the photosensitizer is as shown in the formula I. The photosensitizer # imgabs0 # and the formula I is prepared from 1-ethyl-2, 3, 3-trimethyl-3H-indolium iodide and tris (4-formylphenyl) amine through a one-step reaction, and the photosensitizer can be rapidly and easily prepared. The QA-26 has A beta affinity at a nanomole level, is specifically combined with A beta aggregate, has a fluorescence net value enhanced by 27 times compared with an A beta monomer, and is expected to be used for early diagnosis and treatment of Alzheimer's disease. QA-26 can sensitively respond to viscosity change in vitro and at a cellular level. Besides, the QA-26 also has an aggregation-induced emission (AIE) effect, strong antibacterial activity and a certain level of antitumor activity, and has the potential of being developed into a photodynamic therapy drug by combining with the excellent singlet active oxygen release performance of the QA-26.
Resumen de: JP2024147610A
To provide antibodies for use in the treatment of neurodegenerative diseases, or pharmaceutical compositions thereof.SOLUTION: The present invention provides compounds and methods targeting human tau, particularly human tau phosphorylated at threonine (217) and isoforms of tau expressed only in the CNS, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of neurodegenerative diseases such as AD, PSP and FTD.SELECTED DRAWING: None
Resumen de: KR20250129282A
본 발명은 루이소체병의 증상을 동반한 알츠하이머병 환자를 정상대조군과 구분하여 진단할 수 있는 영상 바이오 마커에 관한 것으로, 보다 상세하게는, 본 발명은 중뇌 흑색질의 도파민 운반체 섭취율(DAT-SN), 및 선조체 조가비핵의 조기 도파민 섭취율 대 지연 도파민 섭취율의 비율(E/D-PP)을 영상 바이오마커로 사용하여 정상대조군과 구별하여 루이소체병의 증상을 동반한 알츠하이머병 환자의 진단 정확도를 높이는 효과를 제공한다.
Resumen de: NZ746574A
The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
Resumen de: US2025268952A1
The present invention aims to provide a method for evaluating dementia and a composition for preventing or treating deterioration in brain function, or for maintaining or improving brain function, and compared the gut microbiota of healthy individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease. As a result, gut microorganisms were selected, such as microorganisms belonging to the genus Faecalibacterium, that are associated with cognitive function. Furthermore it was revealed that Faecalibacterium prausnitzii, possessing specific DNA, exhibited an improvement effect against brain function deterioration, such as learning and memory disorders.
Resumen de: WO2025179300A1
Methods, compositions, and kits are capable of detecting, identifying, diagnosing, prognosing, assessing, monitoring, and/or treating a neurological injury such as acute TBI and distinguishing geriatric TBI from conditions such as dementia, Alzheimer's Disease, Parkinson's disease and the like. Also disclosed are methods of testing elderly patients who have or are suspected of having traumatic brain injury using panels of biomarkers that distinguish TBI from dementia, and, optionally, treating such patients for TBI or dementia based upon the results of the biomarker tests.
Resumen de: US2025270301A1
The invention relates to isolated recombinant peptides comprising an epitope from human tau 2N4R. The invention also relates to antibodies, specific for isolated recombinant peptides comprising an epitope from human tau 2N4R and to such antibodies for use in investigation, diagnosis and treatment of tauopathies, such as Alzheimer's disease.
Resumen de: US2025268982A1
Non-aggregating protein analogues of proteins involved in a proteinopathy, for example Alzheimer's disease, are provided. The protein has a beta-sheet aggregation domain, and the non-aggregating protein analogue has a beta-sheet destabilizing modification in the beta-sheet aggregation domain but substantially retains wild type protein function. The beta-sheet destabilizing modification can be a substitution of a naturally occurring amino acid for a non-naturally occurring amino acid. Methods of treating a proteinopathy using the non-aggregating protein analogues and methods of designing a non-aggregating protein analogue are provided.
Resumen de: US2025270618A1
Provided herein are methods for diagnosing and treating Alzheimer's disease in a subject comprising determining the expression level of three, four or five members of a panel of proteins in a biological sample obtained from the subject.
Resumen de: US2025271453A1
A protein antigen combination containing SERF2 and applications thereof in the field of biological detection are disclosed. The antigen combination for detecting autoantibodies can distinguish Alzheimer's disease (AD) from frontotemporal dementia (FTD) and dementia with Lewy bodies (DLB), and the antigen combination at least includes protein fragments of SERF2. The new protein antigen composition can not only effectively identify patients with AD, but also effectively distinguish AD from FTD and DLB, enabling accurate identification of AD. It is of great importance in terms of diagnostic applications and research.
Resumen de: CN119998661A
In a first aspect, the present invention relates to a method for identifying a subject suffering from or at risk of developing Alzheimer's dementia (AD), the method comprising: (a) determining in a first bodily fluid sample of the subject at least an amount of a compound having a mass of 110.0367 in grams/mole; (b) determining an amount of the same compound as in (a) in a second body fluid sample of the subject; (c) determining a change in the amount of the compound determined according to (a) compared to the corresponding amount of the compound determined according to (b); (d) analyzing the change determined in (c) using a computer-implemented prediction algorithm capable of predicting AD in the subject based on the compound, thereby identifying a subject having AD or at risk of developing Alzheimer's dementia if AD is predicted; wherein the first body fluid sample is obtained prior to administration of thietherazine or a pharmaceutically acceptable salt thereof, and the second body fluid sample is obtained after administration of thietherazine or a pharmaceutically acceptable salt thereof to the subject.
Resumen de: CN120539427A
The invention discloses application of MIGA2 as a therapeutic target in a medicine for preventing and treating Alzheimer's disease, and belongs to the technical field of biological medicine. The MIGA2 gene is used as a therapeutic target to be applied to development, screening or preparation of drugs for preventing and treating Alzheimer's disease. After an MIGA2 overexpression plasmid is adopted to transfect an Alzheimer's disease cell model, it is found that autophagy flow in cells can be promoted and accumulation of related toxic proteins can be reduced, it is proved that MIGA2 has the neuroprotective effect on the Alzheimer's disease, and a new way and exploration direction are provided for treatment of the Alzheimer's disease.
Resumen de: CN120536571A
The invention discloses a system, equipment or medium for diagnosing or predicting Alzheimer's disease based on gene marker combination, and belongs to the technical field of tumor markers. Wherein the gene marker combination comprises TMEM74, CBLN4, SYDE2, SLFNL1, PITPNM3, MPPED1, SYNDIG1L, ADAMTS5, BMX, GLUL, KRT79, TULP2, PRSS16, IL25, KCNJ16, SLC22A25, CRYAA, DLX2, SHISA6, CRYGA, EFCAB3, GMFB, RIN1, DMRTA1, CER1, CYP26B1, REG3A, HTRA3, SLC2A4, CRYGB and SOX3. The invention further discloses a method for detecting the gene marker combination. The expression level data of the gene marker combination is utilized to construct a machine learning model, and the machine learning model can be used for diagnosing whether a subject suffers from the Alzheimer's disease or predicting whether the subject has the risk of suffering from the Alzheimer's disease, and has huge clinical application value.
Nº publicación: CN120536566A 26/08/2025
Solicitante:
SHENZHOU MEDICAL BIOTECHNOLOGY BEIJING CO LTD
\u795E\u5DDE\u533B\u7597\u751F\u7269\u79D1\u6280\uFF08\u5317\u4EAC\uFF09\u6709\u9650\u516C\u53F8
Resumen de: CN120536566A
The invention relates to an A beta 42-A beta 40 detection kit based on a DNAzyme-RCA dissolution curve method and application of the A beta 42-A beta 40 detection kit, and relates to the technical field of biological detection. Comprising an immune-nucleic acid compound assembly, an RCA reaction reagent, Taqman probe systems with different Tm values and a buffer solution, the immune-nucleic acid compound component comprises an A beta 42 immune-nucleic acid compound component and an A beta 40 immune-nucleic acid compound component. According to the invention, high-sensitivity and high-specificity quantitative detection of Abeta42 or Abeta40 is realized, so that powerful support is provided for early diagnosis and illness monitoring of Alzheimer's disease.
BOPI
Sede Electrónica
